CD44 and breast cancer: Although the effect of andrographolide on the BCSCs is quite remarkable, its CC50 value of 0.32 mM in the CD24-/CD44+ BCSCs is higher than the doses of most marketed drugs against breast cancer that are effective at a lower concentration.